Furthermore, db/db mice treated with Ex-4, a glucagon-like peptide-1 receptor (GLP-1R) agonist implicated in the development of NASH, exhibited a decrease in D5D activity and elevated levels of LA, GAL, and DGLA, but not AA [35]. Here, GAL is linked to metabolic dysfunction-associated steatohepatitis.